SEARCH

SEARCH BY CITATION

References

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 16778.
  • 2
    Homma Y, Nishizawa O, Yamaguchi O. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. J. Jpn Neurogenic Bladder Soc. 2003; 14: 27889.
  • 3
    Van Kerrebroeck P, Abrams P, Chaikin D et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 17983.
  • 4
    Research Group on the Standardization of Urological Treatment. EBM-based Guidelines for the Treatment of Benign Prostatic Hyperplasia. 2001, Jiho.
  • 5
    Guideline Committee for Male Lower Urinary Tract Symptoms of the Japan Neurogenic Bladder Society (ed.). Clinical Guidelines for Male Lower Urinary Tract Symptoms. Blackwell Publishing, Oxford, 2008.
  • 6
    Guideline Committee for Overactive Bladder of the Japan Neurogenic Bladder Society (ed.). Clinical Guidelines for Overactive Bladder. Blackwell Publishing, Oxford, 2005.
  • 7
    Guideline Committee for Overactive Bladder of the Japan Neurogenic Bladder Society (ed.). The Digest of the Revised Clinical Guidelines for Overactive Bladder. Blackwell Publishing, Oxford, 2008.
  • 8
    Guideline Committee of the Society of Interstitial Cystitis of Japan (ed.). Guidelines for the Management of Interstitial Cystitis. Blackwell Publishing, Oxford, 2007.
  • 9
    Appell RA, Sand PK. Nocturia: etiology, diagnosis, and treatment. Neurourol. Urodyn. 2008; 27: 349.
  • 10
    Weiss JP, Blaivas JG. Nocturia. Curr. Urol. Rep. 2003; 4: 3626.
  • 11
    Reynard J. Fluid balance therapy of nocturia in women. Int. Urogynecol. J. 1999; 10: 438.
  • 12
    Sugaya K, Nishijima S, Oda M, Miyazato M, Ogawa Y. Change of blood viscosity and urinary frequency by high water intake. Int. J. Urol. 2007; 14: 4702.
  • 13
    Matthiesen TB, Rittig S, Nørgaard JP, Pedersen EB, Djurhuus JC. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J. Urol. 1996; 156: 12929 (Level III).
  • 14
    Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol. Urodyn. 2006; 25: 1059 (Level I).
  • 15
    Tani M, Hirayama A, Fujimoto K, Torimoto K, Akiyama T, Hirao Y. Increase in 24-h urine production/weight causes nocturnal polyuria due to impaired function of antidiuretic hormone in elderly men. Int. J. Urol. 2008; 15: 1515 (Level V).
  • 16
    Kallas HE, Chintanadilok J, Maruenda J, Donahue JL, Lowenthal DT. Treatment of nocturia in the elderly. Drugs Aging 1999; 15: 42937.
  • 17
    Richardson DW, Robinson AG. Desmopressin. Ann. Intern. Medical. 1985; 103: 22839.
  • 18
    Ferring AB. Desmopressin (Minirin®, DDAVP®): Focus on Urological Indications. Adis International Ltd, Chester, 1998.
  • 19
    Vilhardt H. Basic pharmacology of desmopressin: a review. Drug Invest. 1990; 2 (Suppl 5): 28.
  • 20
    Seif SM, Zenser TV, Ciarochi FF, Davis BB, Robinson AG. DDAVP (1-desamino-8-D-argininevasopressin) treatment of central diabetes insipidus – mechanism of prolonged antidiuresis. J. Clin. Endocrinol. Metab. 1978; 46: 3818.
  • 21
    Fjellestad-Paulsen A, Höglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. (Oxf.) 1993; 38: 17782.
  • 22
    Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int. 1999; 83: 5915 (Level II).
  • 23
    Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int. 1999; 84: 204 (Level II).
  • 24
    Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002; 89: 85562 (Level I).
  • 25
    Lose G, Lalos O, Freeman RM, Van Kerrebroeck P, the Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am. J. Obstet. Gynecol. 2003; 189: 110613 (Level I).
  • 26
    Hvistendahl GM, Riis A, Nørgaard JP, Djurhuus JC. The pharmacokinetics of 400 µg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int. 2005; 95: 8049 (Level II).
  • 27
    Johnson TM II, Burridge A, Issa MM, Miller M, Tang T, Ouslander JG. The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study. J. Am. Geriatr. Soc. 2007; 55: 5629 (Level II).
  • 28
    Van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff J, Riis A, Nørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur. Urol. 2007; 52: 2219 (Level I).
  • 29
    Lose G, Mattiasson A, Walter S et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J. Urol. 2004; 172: 10215 (Level III).
  • 30
    Shindel A, Tobin G, Klutke C. Hyponatremia associated with desmopressin for the treatment of nocturnal polyuria. Urology 2002; 60: 344iiii (Level V).
  • 31
    Fujikawa K, Kasahara M, Matsui Y, Takeuchi H. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand. J. Urol. Nephrol. 2001; 35: 31013 (Level II).
  • 32
    Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br. J. Urol. 1998; 81: 21518 (Level II).
  • 33
    Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br. J. Urol. 1988; 62: 1457 (Level II).
  • 34
    Hunsballe JM, Rittig S, Pedersen EB, Olesen OV, Djurhuus JC. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J. Urol. 1997; 158: 8306 (Level III).
  • 35
    Guideline Committee for Overactive Bladder of the Japan Neurogenic Bladder Society (ed.). Clinical Guidelines for Overactive Bladder. Blackwell Publishing, Oxford, 2005. The digest of the revised Clinical Guidelines for Overactive Bladder. Blackwell Publishing, Oxford, 2008.
  • 36
    Homma Y, Kakizaki H, Gotoh M, Takei M, Yamanishi T, Hayashi K. Epidemiologic survey on urination. J. Jpn Neurogenic Bladder Soc. 2003; 14: 26677.
  • 37
    Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003; 92: 94854.
  • 38
    Asplund R. Pharmacotherapy for nocturia in the elderly patient. Drugs Aging 2007; 24: 32543.
  • 39
    Hirayama A, Fujimoto K, Matsumoto Y, Hirao Y. Nocturia in men with lower urinary tract symptoms is associated with both nocturnal polyuria and detrusor overactivity with positive response to ice water test. Urology 2005; 65: 10649 (Level II).
  • 40
    Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006; 176: 36773 (Level III).
  • 41
    Thüroff JW, Chartier-Kastler E, Corcus J et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J. Urol. 1998; 16 (Suppl 1): S4861.
  • 42
    Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A on behalf of the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 41421 (Level I).
  • 43
    Swift S, Garely A, Dimpfl T, Payne C, on behalf of the Tolterodine Study Group. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int. Urogynecol. J. 2003; 14: 505 (Level I).
  • 44
    Homma Y, Paick JS, Lee JG, Kawabe K, on behalf of the Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo controlled trial. BJU Int. 2003; 92: 7417 (Level I).
  • 45
    Yamaguchi O, Marui E, Kakizaki H et al. on behalf of the Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007; 100: 57987 (Level I).
  • 46
    Chapple CR, Rechberger T, Al-Shukri S et al. on behalf of the YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93: 30310 (Level I).
  • 47
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. for the STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. 2005; 48: 46470 (Level I).
  • 48
    Cardozo L, Chapple CR, Toozs-Hobson P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000; 85: 65964 (Level I).
  • 49
    Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. 2004; 45: 4209 (Level I).
  • 50
    Takayasu H, Ueno A, Tsuchida S et al. Clinical evaluation of propiverine hydrochloride (P-4) for treatment of urinary frequency and incontinence – a multicenter, double-blind study with placebo tablets as control. Jpn J. Clin. Exp. Med. 1990; 153: 45971 (Level I).
  • 51
    Saito H, Yamada T, Oshima H et al. Comparison of efficacy and safety between monotherapy with tamsulosin hydrochloride (Harnal Capsule) and combination therapy with propiverine hydrochloride (BUP-4 Tablets) and tamsulosin hydrochloride in patients with benign prostatic hyperplasia accompanied by urinary frequency and incontinence. Jpn J. Urol. Surg. 1999; 12: 52536 (Level I).
  • 52
    Johnson TM II, Burgio KL, Redden DT, Wright KC, Goode PS. Effects of behavioral and drug therapy on nocturia in older incontinent women. J. Am. Geriatr. Soc. 2005; 53: 84650 (Level II).
  • 53
    Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur. Urol. 2007; 51: 90714.
  • 54
    Davila GW, Sand PK, Gonick CW, Parker RL, Dahl NV. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from MATRIX Study. Obstet. Gynecol. 2006; 107 (Suppl): 76S (Level V).
  • 55
    Wang AC, Chih S-Y, Chen M-C. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo controlled trial. Urology 2006; 68: 9991004 (Level II).
  • 56
    Michel MC, De La Rosette JJMCH, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur. Urol. 2005; 48: 11015 (Level II).
  • 57
    Michel MC, Oelke M, Goepel M, Beck E, Burkart M. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol. Urodyn. 2007; 26: 1905 (Level II).
  • 58
    Kreder KJ Jr, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int. 2003; 92: 41821 (Level I).
  • 59
    Song C, Park JT, Heo KO, Lee KS, Choo M-S. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J. Korean Med. Sci. 2006; 21: 10603 (Level II).
  • 60
    Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z, on behalf of the 037 Study Group. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. 2006; 97: 12626 (Level I).
  • 61
    Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, on behalf of the 037 Study Group. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67: 7316 (Level I).
  • 62
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (l VOLT). Clin. Ther. 2006; 28: 193546 (Level II).
  • 63
    Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann. Pharmacother. 2007; 41: 3919 (Level I).
  • 64
    Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int. J. Clin. Pract. 2006; 60: 95966 (Level I).
  • 65
    Wagg A, Wyndaele J-J, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am. J. Geriatr. Pharmacother. 2006; 4: 1424 (Level I).
  • 66
    Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. 2005; 48: 4837 (Level I).
  • 67
    Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int. Urogynecol. J. 2007; 18: 73741 (Level I).
  • 68
    Nishizawa O, Yamamoto T, Suzuki A. Introduction of therapeutic approaches. Imidafenacin. Voiding Disord. Digest. 2008; 16: 2515.
  • 69
    Takeda M, Takahashi S, Nishizawa O, Gotoh M, Yoshida M. Imidafenacin, a novel anticholinergic, significantly improves both nocturia and sleep disorders in OAB patients – EPOCH (Evaluation of anticholinergics in patients with overactive bladder and nocturia for cared-health) study. Jpn J. Urol. Surg. 2009; 22: 5360 (Level V).
  • 70
    Fehrmann-Zumpe P, Karbe K, Blessman G. Using flavoxate as primary medication for patients suffering from urge symptomatology. Int. Urogynecol. J. 1999; 10: 915 (Level III).
  • 71
    Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J. Urol. 1996; 156: 94752 (Level II).
  • 72
    Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J. Urol. 2000; 164: 6769 (Level II).
  • 73
    Payne CK, Mosbaugh PG, Forrest JB et al. for the ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis). Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J. Urol. 2005; 173: 15904 (Level II).
  • 74
    Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J. Urol. 2006; 176: 17785 (Level III).
  • 75
    Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiß C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol. Urodyn. 2006; 25: 11015 (Level V).